HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China’s Ophthalmic Hospital Market – The Major Players, the Business Logic and the Outlook

China Healthcare Weekly (Dec.8) - Important Trends in Pharma, Big Discount Sale of Equity, Topchoice

Shijiazhuang Yiling Pharmaceutical (002603.CH) - Valuation Rebound Is Worth Looking Forward To

Wuxi Biologics (2269.HK) 23H1 - The Positives, the Negatives and the Outlook

WuXi XDC (2268.HK) - How Long Will the Rally Last?

Wuxi Biologics (2269.HK) - Investor Day Brings New Surprises

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Equity Bottom-Up

<ul>
<li>It seems that investors have completely lost patience with WuXi Bio after the Company made new business updates. WuXi Bio’s transparency, communication strategy and expectation management need to be improved.</li>
<li>Although the decline in performance is an important reason for the sharp drop in stock price, we think there're still some deep-seated reasons that investors should pay extra attention to.</li>
<li>Fed's interest rate cut doesn’t necessarily mean immediate improvement in financing environment. In the CXO industry downcycle, whether WuXi Bio can achieve positive turnaround in 24H2 remains to be seen.  </li>
</ul>


It seems that investors have completely lost patience with WuXi Bio after the Company made new business updates. WuXi Bio’s transparency, communication strategy and expectation management need to be improved.
Although the decline in performance is an important reason for the sharp drop in stock price, we think there're still some deep-seated reasons that investors should pay extra attention to.
Fed's interest rate cut doesn’t necessarily mean immediate improvement in financing environment. In the CXO industry downcycle, whether WuXi Bio can achieve positive turnaround in 24H2 remains to be seen.  


Wuxi Biologics (2269.HK) - The Business Update Has Torn Away the Last Fig Leaf